<DOC>
	<DOCNO>NCT02128932</DOCNO>
	<brief_summary>This trial conduct Africa , North South America , Asia Europe . The purpose trial compare effect once-weekly dosing two dose level semaglutide versus insulin glargine once-daily glycaemic control 30 week treatment insulin-naïve subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Semaglutide Once Weekly Versus Insulin Glargine Once Daily add-on Metformin With Without Sulphonylurea Insulin-naïve Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female , 18 year old time signing informed consent Insulinnaïve subject diagnose type 2 diabetes stable diabetes treatment metformin metformin SU ( metformin 1500 mg high maximum tolerate dose SU half maximum allow dose accord national label high ) least 90 day screen . Stable define unchanged medication unchanged dose HbA1c 7.0 10.0 % ( 53 86 mmol/mol ) inclusive Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) throughout trial include 5 week followup period Any disorder , opinion Investigator might jeopardise subject 's safety compliance protocol Treatment glucose lower agent ( ) state inclusion criterion period 90 day screen . An exception shortterm treatment ( 7 day less total ) insulin connection intercurrent illness History chronic idiopathic acute pancreatitis Screening calcitonin value great equal 50 ng/L Personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2 Severe renal impairment define estimate glomerular filtration rate ( eGFR ) less 30 mL/min/1.73 m^2 per modification diet renal disease ( MDRD ) formula ( 4 variable version ) Acute coronary cerebrovascular event within 90 day randomisation Heart failure , New York Heart Association Class IV Known proliferative retinopathy maculopathy require acute treatment accord opinion investigator Diagnosis malignant neoplasm previous 5 year ( except basal cell skin cancer squamous cell skin cancer ) Mental inability , unwillingness language barrier preclude adequate understanding compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>